Inferring evolutionary trajectories from cross-sectional transcriptomic data to mirror lung adenocarcinoma progression

PLoS Comput Biol. 2023 May 25;19(5):e1011122. doi: 10.1371/journal.pcbi.1011122. eCollection 2023 May.

Abstract

Lung adenocarcinoma (LUAD) is a deadly tumor with dynamic evolutionary process. Although much endeavors have been made in identifying the temporal patterns of cancer progression, it remains challenging to infer and interpret the molecular alterations associated with cancer development and progression. To this end, we developed a computational approach to infer the progression trajectory based on cross-sectional transcriptomic data. Analysis of the LUAD data using our approach revealed a linear trajectory with three different branches for malignant progression, and the results showed consistency in three independent cohorts. We used the progression model to elucidate the potential molecular events in LUAD progression. Further analysis showed that overexpression of BUB1B, BUB1 and BUB3 promoted tumor cell proliferation and metastases by disturbing the spindle assembly checkpoint (SAC) in the mitosis. Aberrant mitotic spindle checkpoint signaling appeared to be one of the key factors promoting LUAD progression. We found the inferred cancer trajectory allows to identify LUAD susceptibility genetic variations using genome-wide association analysis. This result shows the opportunity for combining analysis of candidate genetic factors with disease progression. Furthermore, the trajectory showed clear evident mutation accumulation and clonal expansion along with the LUAD progression. Understanding how tumors evolve and identifying mutated genes will help guide cancer management. We investigated the clonal architectures and identified distinct clones and subclones in different LUAD branches. Validation of the model in multiple independent data sets and correlation analysis with clinical results demonstrate that our method is effective and unbiased.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung* / genetics
  • Adenocarcinoma of Lung* / pathology
  • Adenocarcinoma* / genetics
  • Cross-Sectional Studies
  • Genome-Wide Association Study
  • Humans
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Transcriptome / genetics

Grants and funding

This study was supported by the National Natural Science Foundation of China (82227802, received by LH) and the National Key Research and Development Program of China (2017YFA0205202, received by LH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.